Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file ·...
-
Upload
truongminh -
Category
Documents
-
view
219 -
download
3
Transcript of Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file ·...
![Page 1: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/1.jpg)
Research Seminars in Medicine Introduction to Pharmacoepidemiology I
Vera Ehrenstein, MPH, DSc Department of Clinical Epidemiology
Aarhus University Hospital Aarhus, Denmark
10 December 2014
![Page 2: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/2.jpg)
Some definitions of SEMINAR • an advanced or graduate course often
featuring informality and discussion • a meeting for giving and discussing
information
http://www.merriam-webster.com/dictionary/seminar
![Page 3: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/3.jpg)
Phases of drug development • Preclinical: Chemical/animal testing • Phase I studies:
– N=20-80 healthy volunteers – Safety, metabolism
• Phase II studies: – N=100s patients – Efficacy, short-term safety – May or may not have control (placebo) group
• Phase III studies (preauthorization): – 1000s patients, main indication – Randomized controlled trials (RCT) – Dose, efficacy: CAN IT WORK?
![Page 4: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/4.jpg)
Phases of drug development
• Phase IV (postauthorization): – all patients, indications – RCT/non-interventional studies – Long-term safety, rare adverse events – Effectveness: DOES IT WORK?
![Page 5: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/5.jpg)
Why not stop after clinical trials?
• Too short to detect long-term side effects • Too small to detect rare side effects • Conducted in selected populations • Few outcomes assessed • Not all indications assessed • Drug interactions are unknown
![Page 6: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/6.jpg)
• Clinical epidemiology: Study of the outcome of illness
• Pharmacoepidemiology: study of the outcome of intervention
Basic question
• Do the benefits of an treatment outweigh its risks?
![Page 7: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/7.jpg)
Pharmacoepidemiology: scope
Application of epidemiologic reasoning, methods, and knowledge to the study of the uses and effects (beneficial and adverse) of drugs (and biologics), vaccines, and devices in human populations.
7
Hartzema, Tilson & Chan. Pharmacoepidemiology and Therapeutic Risk Management 2008
![Page 8: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/8.jpg)
Types of study by aim • Uses: drug utilization – descriptive studies
– Demographics – Comorbidities – Contraindications – Off-label use
8
![Page 9: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/9.jpg)
Drug utilization
![Page 10: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/10.jpg)
![Page 11: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/11.jpg)
Types of study by aim • Uses: drug utilization – descriptive studies
– Demographics – Comorbidities – Contraindications – Off-label use
• Effects (intended and not) – analytic studies – Additional indications (postmarketing RCT) – Effectiveness for main indication (in real clinical
practice) – Safety: adverse effect monitoring/pharmacovigilance – Comparative effectiveness (active comparators)
11
![Page 12: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/12.jpg)
Schneew
eiss, S., J. J. G
agne, R. J. G
lynn, M. R
uhl and J. A.
Rassen. A
ssessing the comparative effectiveness of new
ly m
arketed medications: m
ethodological challenges and implications
for drug development. C
lin Pharm
acol Ther. 2011 90(6): 777-790.
Immediate postmarketing
period
![Page 13: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/13.jpg)
Patient population over time
Schneeweiss et al . Clin Pharmacol Ther. 2011 90(6): 777-790.
”… early users of newly marketed medications may be highly differential with respect to the benefits and adverse effects of alternative treatment.”
![Page 14: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/14.jpg)
‘The Catch 22’ of risk-benefit assessment
• Need to prescribe a drug in real-life settings to get reliable data on benefit-risk profile
• Reluctance to prescribe the drug without reliable data on benefit/risk profile
![Page 15: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/15.jpg)
Sources of safety ‘signals’
• Spontaneous reporting • Case reports (thalidomide) • Pharmacoepidemiologic studies • Safety surveillance, monitoring using
electronic health data (EHR) – pharmacovigilance
![Page 16: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/16.jpg)
Nordic National Health Registers
1943 1953 1955 1960
SE IS FI DK Cancer Registers
1973 1987 1967
FI
IS SE
DK NO Medical Birth Registers
1971
IS
1969
FI
1951
NO
1961
SE
1943
DK Cause of Death Registers
Courtesy of Associate Professor H
elle Kieler
NO
1994 1994/5 2003 2004 2005
FI DK IS NO SE
Prescribed Drug Registers
1967
FI
1977
DK
1987
SE
Patient Registers NO
2009
![Page 17: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/17.jpg)
Advantages of Nordic data
• Total population coverage • Prospective and routine data collection • Universal health care • Individual-level linkage • At least one component is absent in:
– Medicare/Insurance/Veterans Admin (US) – General Practice Databases (UK, NL) – Regional claims databases (Canada)
![Page 18: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/18.jpg)
![Page 19: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/19.jpg)
![Page 20: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/20.jpg)
97
4
87
61
262
Total studies 515 More than 1 country 4 (!)
What’s wrong with this picture?
![Page 21: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/21.jpg)
Non-Nordic databases: Why? • Collaboration/requirement for funding • Not all variables measured • Homogeneous population (ethnicity) • Not enough data!
![Page 22: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/22.jpg)
Europe - UK
• CPRD – Clinical Practice Research Datalink (formerly General Practice Research Database)
• THIN – The Health Information Network
![Page 23: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/23.jpg)
The Clinical Practice Research Datalink (CPRD)
• Since 1987 • Ca. 600 GP-practices in England
• Approx. 6% of UK population
• 11 mio ‘research standard’ patients/67 mio person-years
• Build-in permanent data checks • Available by license ($$) www.cprd.com
![Page 24: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/24.jpg)
CPRD – type of data
• Administrative: birth date, practice membership dates, deaths
• Clinical: diagnoses, including those from specialists and hospital stays
• Medications: issued prescriptions – with prescribed dose
• Laboratory data • Lifestyle: BMI, smoking, alcohol use
![Page 25: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/25.jpg)
Europe - NL
• IPCI – The Integrated Primary Care Information Database
• PHARMO Record Linkage System • IADB – pharmacy dispensing database • MONDRIAAN project
![Page 26: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/26.jpg)
The IPCI database • Participating general practitioners
(voluntary) • Since 1994/ 1.5 mio patients (also
historical) • Diagnoses, labs, referrals • Indications for prescriptions • Managed by Erasmus University
(access) http://www.ipci.nl
![Page 27: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/27.jpg)
EU databases: strengths
• Rich clinical data, including anthropometrics
• Primary and secondary-care diagnoses are often available
• Laboratory data
• Lifestyle data (smoking, alcohol use)
• For medications: indication and prescribed dose
![Page 28: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/28.jpg)
EU databases: limitations
• GP databases subject to follow-up loss (practice changes)
• No lifelong follow-up
• Linkage not straightforward
• No linkage to non-medical data
![Page 29: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/29.jpg)
US data sources for PE
• Health maintenance organizations (HMO)
• Medicare and Medicaid
• Veterans Administration (VA)
![Page 30: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/30.jpg)
Health Maintenance Organizations (HMO)
• Insurance-company ‘managed care’ health
care plan • Primary care provided = gatekeeper • Closed network of healthcare providers
![Page 32: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/32.jpg)
Type of Data
• Administrative • Birth date, sex, enrollment dates
• Claims (billing e-records of medical encounters) • Pharmacy dispensing (NDC) • Diagnoses from hospitalizations/ambulatory
visits (ICD) • Electronic medical records (EMR)
• Detailed clinical data (procedures, labs, radiology, referrals, BMI, health behaviors)
NDC=national drug codes, ICD=international classification of diseases
![Page 33: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/33.jpg)
Strom
. Pharm
acoepidemiology, 5
th edition
![Page 34: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/34.jpg)
HMOs: strengths
34
• Large and diverse samples • Broad population coverage • Ability to re-contact members • Rich clinical data • Standard data layouts facilitate
multicenter-research
![Page 35: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/35.jpg)
HMOs: limitations
35
• Uninsured are not represented (unemployed, selection bias)
• Gaps in coverage (employment-based) • Outsourced and out-of-pocket services
not represented • Completeness may vary
![Page 36: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/36.jpg)
US Government claims
36
• Medicaid – est. 1965, a payer plan • Medicare – est. 1965, a payer plan • Department of Veterans Affairs (VA)
Health Care System – est. 1930, a payer/provider plan
![Page 37: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/37.jpg)
Medicaid
37
• Largest US-government funded health coverage (ca. 60 mio)
• Eligibility: low-income pregnant women, poor families with children, chronically disabled, low-income
• State-administered • Low-income definitions/benefits offered vary
by state
![Page 38: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/38.jpg)
Medicare
38
• Funded 100% by the US federal gov’t • Eligibility: age 65+, some disabilities, end-
stage-renal disease, amyotrophic lateral sclerosis
• Parts A, B, C, D cover different types of care
• Most require co-payment or deductible
![Page 39: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/39.jpg)
Veterans Affairs (VA)
39
• A large integrated health care system (medicine, surgery, rehab, medications)
• A provider of health services, funded by US gov’t
• Eligibility: US military veterans, >90% men
![Page 40: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/40.jpg)
Strom
. Pharm
acoepidemiology, 5
th edition
![Page 41: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/41.jpg)
Combining databases: examples
• FDA Mini-Sentinel Program (USA) • EU-ADR – Exploring and Understanding
adverse drug reactions (Europe) • OMOP – Observational Medical Outcome
Partnership (USA) • …Many more!
![Page 42: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/42.jpg)
Principles of combining data
• Harmonization of protocol/code – exposure, outcome, covariates
• Harmonization of data management – common data model (CDM)
• Data sharing via a common platform
Trifi
ro e
t al.
J In
tern
Med
. 201
4 2
75(6
): 55
1-56
1.
![Page 43: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/43.jpg)
![Page 44: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/44.jpg)
The FDA Sentinel Initiative • 2007 - FDA Amendments Act (FDAAA),
mandating FDA to establish an active surveillance system for monitoring drugs, using electronic health records (EHR).
• Goal: a streamlined infrastructure to harness
the data in existing automated HER to actively monitor the safety of medical products continuously and in real-time.
http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm
![Page 45: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/45.jpg)
Mini-Sentinel
• Pilot project of the Sentinel Initiative Focus on • Assessments - Medical product exposures,
health outcomes, and links between them • Methods - for identifying, validating, and linking
medical product exposures and health outcomes • Data - Mini-Sentinel Distributed Dataset and
tools used to access the data http://mini-sentinel.org/
![Page 46: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/46.jpg)
The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction
Pharmacoepidemiology and Drug Safety pages 1-8, 19 JAN 2012 DOI: 10.1002/pds.2343 http://onlinelibrary.wiley.com/doi/10.1002/pds.2343/full#pds2343-fig-0001
![Page 47: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/47.jpg)
Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project
Pharmacoepidemiology and Drug Safety Volume 20, Issue 1, pages 1-11, 8 NOV 2010 DOI: 10.1002/pds.2053 http://onlinelibrary.wiley.com/doi/10.1002/pds.2053/full#fig2
![Page 48: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/48.jpg)
Common database model (CDM).
Avillach P et al. J Am Med Inform Assoc 2013;20:184-192
Copyright © by the American Medical Informatics Association. All rights reserved.
Customizable!!!
![Page 49: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/49.jpg)
Data extraction algorithms, benchmarking, language mining
![Page 50: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/50.jpg)
![Page 51: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/51.jpg)
Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Journal of Internal Medicine Volume 275, Issue 6, pages 551-561, 27 MAY 2014 DOI: 10.1111/joim.12159 http://onlinelibrary.wiley.com/doi/10.1111/joim.12159/full#joim12159-fig-0001
![Page 52: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/52.jpg)
Advantages of multidatabase-monitoring with CDM
• Numbers: rare/weak/null associations • Diversity: populations/exposures/data type • Speed: (rofecoxib & MI) • Standardization: Same protocol/data/analyst • Efficiency: avoiding work duplication • Control: data custodian retains data • Privacy: patient protection issues addressed
Trifi
ro e
t al.
J In
tern
Med
. 201
4 2
75(6
): 55
1-56
1.
![Page 53: Research Seminars in Medicine Introduction to Pharmacoepidemiology I · PDF file · 2014-12-12Research Seminars in Medicine Introduction to Pharmacoepidemiology I Vera Ehrenstein,](https://reader034.fdocuments.us/reader034/viewer/2022052608/5ab95cbd7f8b9aa6018dc6f1/html5/thumbnails/53.jpg)
Take-home message • Most of the knowledge about benefits and risks
of treatments comes from non-experimental studies
• This type of research nearly exlcusively relies on data from routine databases.
• One database (country) is often insufficient • Methodological developments follow the trend of
multi-database research (Big Data) • ”The future ain’t what it used to be”
Yogi Berra as quoted by J Gagne, Epidemiology 2013